Medpace vs Mettler Toledo
Medpace (MEDP) and Mettler Toledo (MTD) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $17.1B
- Last close
- $610.54
- 12 months
- +4.2%
- Market value
- $33.2B
- Last close
- $1,666.88
- 12 months
- +19.1%
At a glance
- The biggest part of Medpace's revenue is Oncology (30%); at Mettler Toledo it is US Operations (37%).
- By market value, Mettler Toledo ($33.2B) is about 1.9 times Medpace ($17.1B).
- Over the last 12 months Medpace's share price moved +4.2% and Mettler Toledo's +19.1%; against the S&P 500 that is −1.6 points and +13.4 points.
- In their last fiscal years Medpace kept 17.8% of revenue as net income and Mettler Toledo 21.6%.
- In the last 90 days insiders reported 0 open-market purchases at Medpace and 0 at Mettler Toledo; members of Congress disclosed 0 trades in Medpace and 0 in Mettler Toledo.
- Next results: Medpace Feb 8, 2027, Mettler Toledo Feb 3, 2027.
How each one makes money: Medpace revenue · Mettler Toledo revenue
Share prices on one chart
Medpace and Mettler Toledo, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Medpace MEDPNASDAQ · Life Sciences Tools & Services | Mettler Toledo MTDNYSE · Life Sciences Tools & Services | |
|---|---|---|
| Size and profitability | ||
| Market value | $17.1B | $33.2B |
| Revenue, last fiscal year | $2.53B | $4.03B |
| Net income, last fiscal year | $451M | $869M |
| Net marginNet income as a share of revenue | 17.8% | 21.6% |
| Free cash flow | $682M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Mettler Toledo against
Common questions
How is Medpace different from Mettler Toledo?
Medpace (MEDP) is in Life Sciences Tools & Services on NASDAQ, with $2.53B of revenue in its last fiscal year and a net margin of 17.8%. Mettler Toledo (MTD) is in Life Sciences Tools & Services on NYSE, with $4.03B of revenue in its last fiscal year and a net margin of 21.6%. The biggest part of Medpace's revenue is Oncology (30%); at Mettler Toledo it is US Operations (37%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Medpace and Mettler Toledo compare in size?
Mettler Toledo has the larger market value: Medpace $17.1B and Mettler Toledo $33.2B, at the last close.
Whose share price rose more over the last 12 months, MEDP or MTD?
Over the last 12 months Medpace moved +4.2% and Mettler Toledo +19.1%. Past price moves say nothing about the future.
Which has had more insider buying, Medpace or Mettler Toledo?
Since 2006, Medpace insiders reported 40 open-market purchases against 23 for Mettler Toledo. These are counts of what was filed, not a view on either stock.
Do members of Congress trade MEDP or MTD?
In the last 12 months, members of Congress disclosed 6 trades in Medpace (MEDP) and 3 in Mettler Toledo (MTD).
When did insiders last buy MEDP and MTD?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Medpace pageMettler Toledo pageRare insider trades this weekAll comparisons
https://oqro.io/compare/medp-vs-mtd







